ETF Channel: Analysts See 19% Upside for iShares US Pharmaceuticals ETF IHE

Analysts see nearly 19% upside for the iShares US Pharmaceuticals ETF (IHE) based on the average analyst 12-month forward target price for its underlying holdings. Three holdings with notable upside to their analyst target prices are Evolus Inc, CorMedix Inc, and Rapport Therapeutics Inc, with potential gains of 220%, 129%, and 90%, respectively. IHE tracks the Dow Jones U.S. Select Pharmaceuticals Index and holds large and mid-cap drug manufacturers, with analysts expecting gains in chronic-disease treatments, specialty biologics, oncology, and neurology.